Compounds > sb t-1213
Page last updated: 2024-12-11

sb t-1213

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9875938
CHEMBL ID126678
MeSH IDM0266565

Synonyms (3)

Synonym
CHEMBL126678
sb-t-1213
[(1s,2s,3r,4s,7r,9s,10s,12r,15s)-4-acetyloxy-1,9-dihydroxy-15-[(2r,3s)-2-hydroxy-5-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hex-4-enoyl]oxy-10,14,17,17-tetramethyl-11-oxo-12-propanoyloxy-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoa

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In this respect various prodrug and drug targeting strategies have been envisioned either to improve oral bioavailability or tumor specific delivery of taxoids."( Improved biochemical strategies for targeted delivery of taxoids.
Ganesh, T, 2007)		0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID422241Resistance factor, ratio of IC50 for P-glycoprotein deficient wild type human MCF7 cells to IC50 for multidrug-resistant human NCI/ADR cells2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Recent advances in the chemistry and biology of new generation taxoids.
AID407746Cytotoxicity against multidrug resistant Pgp expressing human NCI/ADR cells after 72 hrs by sulforhodamine B test2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Design, synthesis, and biological evaluation of new-generation taxoids.
AID121293Tumor growth delay of B16 melanoma implanted sc in B6D2F1 mice when 0.4 mL/mouse administered i.v. on day 7 at 7.7 mg/kg/day1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID115246Log cell kill = T-C(days)/3.32xTd (Tumor doubling time in days, 1.4 in this assay )on day 9 at 4.8 mg/kg/day in B16 melanoma implanted sc in B6D2F1 mice1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID106479Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID121395Tumor growth inhibition of B16 melanoma implanted sc in B6D2F1 mice when 0.4 mL/mouse administered i.v. on day 9 at 4.8 mg/kg/day1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID103574In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Tumor-specific novel taxoid-monoclonal antibody conjugates.
AID260667Efficacy against Pgp+ human colon tumor xenograft DLD1 in SCID mice at 240 mg/kg, iv2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents.
AID103916Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID407747Resistance index, Ratio of IC50 for multidrug resistant Pgp expressing human NCI/ADR cells to IC50 for Pgp deficient human MCF7 cells2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Design, synthesis, and biological evaluation of new-generation taxoids.
AID121294Tumor growth delay of B16 melanoma implanted sc in B6D2F1 mice when 0.4 mL/mouse administered i.v. on day 9 at 4.8 mg/kg/day1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID310979Cytotoxicity against human A549 cells2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Improved biochemical strategies for targeted delivery of taxoids.
AID121290Tumor growth delay of B16 melanoma implanted sc in B6D2F1 mice when 0.4 mL/mouse administered i.v. on day 5 at 12.4 mg/kg/day1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID422240Cytotoxicity against multidrug-resistant human NCI/ADR cells after 72 hrs2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Recent advances in the chemistry and biology of new generation taxoids.
AID260666Cytotoxicity against human mammary tumor cell line MCF7-R2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents.
AID115117Log cell kill = T-C(days)/3.32xTd (Tumor doubling time in days, 1.4 in this assay ) on day 5 at 12.4 mg/kg/day in B16 melanoma implanted sc in B6D2F1 mice1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID8674In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Tumor-specific novel taxoid-monoclonal antibody conjugates.
AID121391Tumor growth inhibition of B16 melanoma implanted sc in B6D2F1 mice when 0.4 mL/mouse administered i.v. on day 5 at 12.4 mg/kg/day1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID260665Cytotoxicity against human mammary tumor cell line MCF7-S2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents.
AID115245Log cell kill = T-C(days)/3.32xTd (Tumor doubling time in days, 1.4 in this assay )on day 7 at 7.7 mg/kg/day in B16 melanoma implanted sc in B6D2F1 mice1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID8657Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID1178133Mitotic arrest in human HeLa cells assessed as apoptosis at 5 nM after 24 hrs by TUNEL assay2014Bioorganic & medicinal chemistry, Sep-15, Volume: 22, Issue:18
Drug discovery targeting cell division proteins, microtubules and FtsZ.
AID310992Cytotoxicity against human A431 cells2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
Improved biochemical strategies for targeted delivery of taxoids.
AID9790Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID83579Concentration required to inhibit growth of human tumor HT-29 (colon) cell line.1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID407745Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Design, synthesis, and biological evaluation of new-generation taxoids.
AID121394Tumor growth inhibition of B16 melanoma implanted sc in B6D2F1 mice when 0.4 mL/mouse administered i.v. on day 7 at 7.7 mg/kg/day1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells.
AID422239Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Recent advances in the chemistry and biology of new generation taxoids.
AID103765In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Tumor-specific novel taxoid-monoclonal antibody conjugates.
AID7898In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Tumor-specific novel taxoid-monoclonal antibody conjugates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's5 (71.43)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.82 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (42.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		5.3670taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
docetaxel
[no description available]		4.2150hydrate;
secondary alpha-hydroxy ketone		antineoplastic agent
idn 5390
IDN 5390: structure in first source		3.1410
sb t-1214
[no description available]		4.0440
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		01.9910
B16 Melanoma
[description not available]		01.9910
Cancer of Ovary
[description not available]		01.9910
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9910
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		01.9910